Top Markets
Coin of the day
Inventiva S.A. Inventiva S.A.

Inventiva S.A.

IVA
Rank in Stocks #8990
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Share Price
$4.74
Last synced: 2026-08-28
Market Cap
$1.12B
Change (1 day)
-5.77%
Change (1 year)
-16.96%
Country
FR
Trade Inventiva S.A. (IVA)

Category

EPS for Inventiva S.A. (IVA)
EPS as of 2026 TTM: 0
According to Inventiva S.A. latest financial reports and stock price the company's current EPS (TTM) is 0. At the end of 2026 the company had a EPS of 0 equal to its 2026 EPS that were of 0.
EPS history for Inventiva S.A. from 2026 to 2026
EPS at the end of each year
Year EPS Change
Not enough data for the provided dates.
EPS for similar companies or competitors
Company EPS EPS Difference Country
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH